Description: Shown to improve survival in colorectal cancerbevacizumab (Avastin) becomes the first anti-angiogenesis agent to prove effective in a randomized Phase III trial. for patients with advanced and metastatic colorectal cancer. New trials are underway patients with previously untreated metastatic colorectal cancer were randomly divided into two

Category: Metastatic Colorectal Cancer

Url: http://www.cancer.gov/clinicaltrials/results/bevacizumab-and-colorectal-cancer0601

Date: Oct 7, 2005

Current Rating: 0.00

Clicks/Hits Received: 0